Skip to content
Research Article Open access CC BY 4.0

Prevalence and Factors Associated with Opportunistic Infections in HIV Positive Patients on Antiretroviral Therapy in Uganda

John Rubaihayo, Nazarius M. Tumwesigye, Joseph Konde-Lule, Henry Wamani, Edith Nakku-Joloba, Fredrick Makumbi

International Journal of TROPICAL DISEASE & Health · pp. 1–13 · Published 8 Jul 2015

10.9734/IJTDH/2015/18953

Abstract

Introduction: Opportunistic infections (OIs) remain the single main cause of ill-health and death among HIV/AIDS patients in resource poor countries. We assessed the prevalence of 17 OIs and associated factors among HIV positive patients on highly active antiretroviral therapy (HAART) in Uganda. Methods: Observational data from 2004 to 2013 for adult HIV positive patients (>=15yrs) obtaining care and treatment from the AIDS support organization (TASO) in Uganda were reviewed.  Electronic data were obtained from TASO HIV clinics representing 4 different geographical areas of Uganda. Descriptive statistics were summarized in terms of frequencies and percentages. Logistic regression was used to assess the factors associated with occurrence of OIs. Results: Between 2004 and 2013, a total of 36,133 HIV patients were enrolled on HAART of which two thirds (66%) were female and one third (34%) were male.  In univariate analysis, significant differences were observed between male and female ART clients with men being older (median age 36yrs IQR 29-43 vs 32 yrs IQR 26-39, p<0.0001); likely to be more educated(>secondary 31% vs 19%, p<0.0001);  likely to be more severely ill(CD4 count<100 26% vs 21%, p<0.0001); were more likely to be married (65% vs 42%, p<0.0001) and were more likely to be formally employed (27% vs 12%,  p<0.0001). Mean annual prevalence for any OI in 2004 was 57.6% and in 2013 was 27.5% (X2trend = 122, b= -0.0283, p <0.0001). The most commonly encountered OIs were geohelminths (35%), diarrhea<1 month (18%) and mycobacterium tuberculosis (11%). Factors associated with any OI after HAART were male gender, if from Northern Uganda, low education (<primary), baseline WHO stages III&IV, stavudine ART regimen, baseline CD4 count <100cells/µl, low baseline weight <55 kg and period 2004-2008 (p<0.05). Conclusion and Recommendations: In these settings, the burden of OIs is still high in spite of increased access to HAART. The prevalence of geohelminthes and diarrhoea is worrying among HIV patients on HAART. Men remain at greater risk of OIs and should be the main target for early HAART initiation.

HIV/AIDS opportunistic infections antiretroviral therapy prevalence TASO Uganda.

References (23)

  1. 1 A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection [DOI]
  2. 2 Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study [DOI]
  3. 3 AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. [DOI]
  4. 4 Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial [DOI]
  5. 5 Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi [DOI]
  6. 6 The impact of malnutrition on survival and the CD4 count response in HIV‐infected patients starting antiretroviral therapy [DOI]
  7. 7 Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study [DOI]
  8. 8 Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort [DOI]
  9. 9 Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda [DOI]
  10. 10 Impact of opportunistic disease on survival in patients with HIV infection [DOI]
  11. 11 Preventing Opportunistic Infections in Human Immunodeficiency Virus-Infected Persons: Implications for the Developing World [DOI]
  12. 12 HIV‐Associated Opportunistic Infections—Going, Going, But Not Gone: The Continued Need for Prevention and Treatment Guidelines [DOI]
  13. 13 Diarrhoea, CD4 Counts and Enteric Infections in a Community-Based Cohort of HIV-Infected Adults in Uganda [DOI]
  14. 14 Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France [DOI]
  15. 15 Survival of HIV-Infected Adolescents on Antiretroviral Therapy in Uganda: Findings from a Nationally Representative Cohort in Uganda [DOI]
  16. 16 Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting [DOI]
  17. 17 Prevalence of Opportunistic Infections and Associated Factors among HIV Positive Patients taking Anti-Retroviral Therapy in DebreMarkos Referral Hospital, Northwest Ethiopia [DOI]
  18. 18 Quality of data collection in a large HIV observational clinic database in sub‐Saharan Africa: implications for clinical research and audit of care [DOI]
  19. 19 Optimal Timing and Best Antiretroviral Regimen in Treatment-naive HIV-Infected Individuals with Advanced Disease [DOI]
  20. 20 Probiotics, Soluble Fiber, and L-Glutamine (GLN) Reduce Nelfinavir (NFV)or Lopinavir/Ritonavir (LPV/r)-related Diarrhea [DOI]
  21. 21 Natural history and clinical presentation of HIV-1 infection in adults.
  22. 22 Changes in the Clinical Spectrum of Opportunistic Illnesses in Persons with HIV Infection in Taiwan in the Era of Highly Active Antiretroviral Therapy [DOI]
  23. 23 Differences in Rates of Diarrhea in Patients with Human Immunodeficiency Virus Receiving Lopinavir‐Ritonavir or Nelfinavir [DOI]

Cited by 4

Opportunistic infections among people living with HIV/AIDS attending antiretroviral therapy clinics in Gedeo Zone, Southern Ethiopia

Genet Gebremichael, Niguse Tadele, Ketema Bizuwork Gebremedhin · BMC Research Notes · 2024

Showing 2 of 4 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

60

Page views

0

PDF downloads

11

Outbound clicks

4

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.